Please wait while the formulary information is being retrieved.
Drug overview for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
Generic name: KIT FOR PREP TC 99M/SESTAMIBI COMBINATION NO.1
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: KIT FOR PREP TC 99M/SESTAMIBI COMBINATION NO.1
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1) have been approved by the FDA:
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
The following dosing information is available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Dextroamphetamine Transdermal/Urinary Alkalinizers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Urinary alkalinizers decrease the renal elimination of dextroamphetamine.(1) CLINICAL EFFECTS: Concurrent use of dextroamphetamine and urinary alkalinizers may result in increased dextroamphetamine levels and side effects. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Coadministration of dextroamphetamine with urinary alkalinizing agents should be avoided.(1) DISCUSSION: Concurrent use of alkalinizing agents with dextroamphetamine decreases the renal elimination of dextroamphetamine. Co-administration of these should be avoided because of the potential of increased actions of dextroamphetamine.(1) |
XELSTRYM |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Sympathomimetics/Urinary Alkalinizers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unionized sympathomimetic amines will be reabsorbed into systemic circulation from the distal tubules of the kidneys. CLINICAL EFFECTS: Enhanced sympathomimetic activity and increased risk of sympathomimetic toxicity. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Watch patient for enhanced sympathomimetic side effects when urinary alkalinizers are concomitantly used. A lower dose of certain sympathomimetics may be required. DISCUSSION: Signs and symptoms of sympathomimetic toxicity include euphoria, confusion, delirium, hallucinations and nervousness. |
AKOVAZ, BENZPHETAMINE HCL, EMERPHED, EPHEDRINE HCL, EPHEDRINE SULFATE, EPHEDRINE SULFATE-0.9% NACL, EPHEDRINE SULFATE-NACL, LISDEXAMFETAMINE DIMESYLATE, MIDODRINE HCL, REZIPRES, VYVANSE |
| Quinidine/Urinary Alkalinizers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Quinidine elimination is impaired by urinary alkalinization. CLINICAL EFFECTS: Potentiation of quinidine effects may be observed. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Monitoring quinidine levels and cardiac function may be indicated. The quinidine dose may need to be adjusted when a urinary alkalinizer is started or stopped. DISCUSSION: Additional documentation is necessary to confirm this potential interaction. |
NUEDEXTA, QUINIDINE GLUCONATE, QUINIDINE SULFATE |
The following contraindication information is available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Bronchospastic pulmonary disease |
| Congenital heart disease |
| Hypocalcemia |
| Metabolic alkalosis |
| Pulmonary hypertension |
There are 0 moderate contraindications.
The following adverse reaction information is available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 9 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Chest pain Vomiting |
| Rare/Very Rare |
|---|
|
Anaphylaxis Angina Angioedema Cardiac arrhythmia Edema Hypotension Seizure disorder |
There are 19 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dysgeusia |
Parosmia |
| Rare/Very Rare |
|---|
|
Acute abdominal pain Arthralgia Bradycardia Dizziness Dyspnea Fatigue Fever Flushing General weakness Headache disorder Injection site sequelae Nausea Pruritus of skin Skin rash Syncope Urticaria Xerostomia |
The following precautions are available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CARDIOLITE (kit for prep tc 99m/sestamibi combination no.1)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool